Oxidative skeletal muscle metabolism in chronic heart failure patients with and without iron deficiency - Oxidative exercise capacity in chronic HF with and without ID

niversitair Medisch Centrum Groningen0 个研究点目标入组 40 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•For HFrEF patients:
•- Diagnosis of chronic HF of either ischemic or non-ischemic etiology;
•- Stable, evidence-based medical therapy for HF;
•- LVEF <40% measured <5 year prior to inclusion;
•- NYHA class II - III (symptomatic HF) at moment of inclusion;
•For HFpEF patients:
•- Diagnosis of chronic HF of either ischemic or non-ischemic etiology;
•- LVEF >40% measured <5 year prior to inclusion;
•- Left atrial volume index (LAVI) >34 mL/m2 or left ventricular mass index >=115
•g/m2 (for males) or >=95 g/m2 (for females) or E/e* >=13 or mean e* (septal and
•lateral) <9 cm/s, as measured on echocardiography <1 year prior to inclusion;
•- NYHA class II - III (symptomatic HF) at moment of inclusion;
•- Serum NT-proBNP >=125 pg/mL when in sinus rhythm; >300 pg/mL when in atrial
•fibrillation.
•Additional inclusion criterion for subjects with ID:
•- Iron deficiency, defined as TSAT <20%.
•For control subjects:
•- No diagnosis of heart failure
•- No diagnosis of severe vascular or (neuro-)muscular disease

•- Age <18 years
•- Unable or unwilling to undergo exercise MRI (e.g. pregnancy, physical
•disabilities, claustrophobia)
•- The presence of ferromagnetic material in/on the body which cannot be removed
•(e.g. non-MRI-compatible cardiac devices, tattoos containing ferrous ink)
•- History of erythropoietin stimulating agent, intravenous iron therapy and/or
•blood transfusion <3 months prior to study enrolment
•- Moderate anaemia, defined as Hb <7 mmol/L for both men and women
•- Oral iron therapy >100 mg/day <4 weeks prior to study enrollment
•- Unable to understand study procedures
•- Unable or unwilling to provide informed consent

发起方